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ABSTRACT
Chlamydia trachomatis is the most common reportable sexually transmitted disease (STD) in the
United States. In the 1980s, rapid diagnostic tests for chlamydia began to replace more cumbersome
tissue culture methods. Current data on rapid antigen detection assays demonstrate acceptable
sensitivity, specificity, and predictive values in populations with a high prevalence of chlamydia.
Few studies report the performance of these assays in a low-prevalence obstetric and gynecologic
(Ob/Gyn) population. This study compares the most commonly used direct fluorescent antibody
(DFA) assay (Syva Microtrak) with tissue culture (TC) in a low-prevalence population. Endocer-
vical specimens (775) were tested from women at risk for chlamydia infection, and the prevalence
was found to be 7.7%. The DFA assay demonstrated a sensitivity of 80% and a specificity of 97%
compared with TC. The positive and negative predictive values were 72% and 98%, respectively.
The results of this study indicate that the Syva DFA assay lacks the sensitivity and positive
predictive value for routine use in Ob/Gyn populations with a low prevalence of C. trachomatis.
(C) 1993 Wiley-Liss, Inc.
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hlamydia trachomatis is the most common re-
portable sexually transmitted disease in the
United States. l’2 Chlamydia is a major public
health problem in the United States, with 3-5 mil-
lion new cases estimated each year
1-3 and an annual
economic burden of more than $1 billion.
4 The
Centers for Disease Control recommends chla-
mydia testing at the first prenatal visit and in the
third trimester for high-risk patients. Clinical
manifestations of the disease affect men, women,
and children. Unfortunately, many genital chla-
mydia infections are asymptomatic in women and
can result in pelvic inflammatory disease, ectopic
pregnancy, and infertility.
3 The gold standard for
detecting chlamydia is tissue culture (TC). 2’3’5
Tissue culture is time consuming and expensive,
and requires technical expertise. In the 1980s,
rapid diagnostic tests for detecting chlamydia began
replacing tissue culture methods. These antigen de-
tection assays are simple to perform and offer rapid
results. Current data on rapid antigen detection
assays demonstrate acceptable sensitivity, specific-
ity, and positive predictive value for routine use in
high-prevalence populations. However, many of
these assays are targeted at the private practitioner
or clinic with a low prevalence of chlamydia infec-
tion. Schachter
6 has stated that nonculture methods
for chlamydia antigen detection are best suited for
high-prevalence populations or high-risk patients
and that extrapolation of these test results to low-
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prevalence populations must be made with caution.
Recently, the American College of Obstetrics and
Gynecology Update (Precis IV) stated that the use
of rapid antigen detection assays in a low-preva-
lence population has not been thoroughly investi-
gated.
7 This paper describes a prospective random-
ized study comparing the Syva Microtrak direct
fluorescent antibody (DFA) test against tissue cul-
ture (TC) in a low prevalence population.
MATERIALS AND METHODS
Study Population
All specimens were collected at Scott & White Me-
morial Hospital, Temple, Texas, from women at
risk for chlamydia infection. Risk factors were:
multiple sex partners, new sex partners, sexually
active adolescents, pregnancy, history of other sex-
ually transmitted disease, or signs of cervicitis.
Samples were not collected from patients who re-
ceived antibiotic therapy within 2 weeks of sam-
pling. Previous studies at this hospital demon-
strated the prevalence of chlamydia in this female
population to be 8%.
Collection of Specimens
All specimens were collected from the endocervix
per manufacturer’s instructions. Dacron swabs
(Medical Wire Equipment Co., Corsham, Wilts,
U.K.) were used for TC. DFA Dacron swabs were
supplied in the Microtrak DFA kit. Collection
order was randomized by the last digit of the med-
ical record number (MRN). If the MRN ended in
an odd number, the TC swab was collected first,
followed by the DFA swab. If the MRN was even,
the order was reversed. If a gonorrhea specimen or
a pap smear was requested, they were collected
prior to the study swabs. Swabs were placed in their
respective transport containers and were tested
within 24 hours of collection simultaneously by the
Syva DFA and TC isolation. Specimens were
stored at 4C until tested.
Laboratory Methods
Cell Culture Methods
Chlamydia cell culture swabs were used to inoculate
McCoy cell monolayers followed by centrifugation
for hour at 3,000g. One milliliter of Chlamydia
Isolator Medium with cycloheximide (Bartels
Immunodiagnostics, Inc., Bellevue, WA)was
added to each culture, which was then incubated at
35-37C for 48-72 hours. A blind second passage
was not performed. Cultures were stained with a C.
trachomatis-specific fluorescent monoclonal anti-
body (Chlamydia Culture Confirmation Kit, Syva
Co., Palo Alto, CA). Positive results were deter-
mined by identifying fluorescent-stained inclusion
bodies. Results were entered in the main laboratory
computer and retrieved after all testing was com-
pleted.
DFA
Slides were processed and stained according to
manufacturer’s instructions (Microtrak, Syva
Co.). Slides were screened with a Zeiss fluorescent
microscope at a 400 magnification and con-
firmed at 1,000. Slides were considered positive
if ten or more elemental bodies were identified. All
slides were processed and read by one of four
American Society of Clinical Pathologists (ASCP)
Certified Medical Technologists experienced with
the Syva DFA system. All technologists are regu-
larly tested against the CAPS (Clinical Association
of Pathologists) survey slides. The DFA results
were interpreted and recorded before TC results
were obtained. DFA specimens were considered
inadequate if less than five endocervical cells were
present on a smear.
Statistical Methods
Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were
calculated for all assays. Statistical significance was
determined by chi square analysis.
RESULTS
A total of 775 endocervical specimens was tested by
DFA and TC. Less than 3% of the original speci-
mens were considered inadequate. These specimens
were excluded from our final calculations. The
prevalence of chlamydia based on TC results was
7.7%.
The DFA demonstrated a sensitivity of 80% and
a specificity of 97%. The positive and negative
predictive values, were 72% and 98%, respectively
(Fig. 1). There were 19 false positives and 12 false
negatives.
DISCUSSION
Many rapid diagnostic tests are available for
chlamydia detection. Tissue culture is still consid-
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Results ofDFA vs TC
TC
DFA
sensitivity (a/a + e) 80%
specificity (d/d + b) 97%
PPV (a/a + b) 72%
NPV (d/c + d) 98%
Fig. I. The results of the Syva DFA for chlamydia detec-
tion versus tissue culture isolation.
ered the gold standard by which all other assays are
judged. To date, no single rapid diagnostic test for
chlamydia has proved ideal for routine screening,
especially in a low-prevalence (<9%) popula-
tion.
7-1
The most commonly used and studied DFA as-
say is the Syva Microtrak C. trachomatis Direct
Specimen Test. Therefore, we elected to study this
test in our low-prevalence population. Despite
published reports 8’ l, 12 that used less than ten ele-
mental bodies per slide to signify a positive DFA
test, we elected to follow the manufacturer’s in-
structions and use ten or more elemental bodies per
slide for a positive test, since the majority of tests
would be conducted in routine clinical laboratories
and not under research protocols. Studies have
shown that sensitivity can be increased by lowering
the number of elemental bodies required for a pos-
itive test, but this is at the expense of lowering the
specificity and positive predictive value.
9
The DFA demonstrated a sensitivity of 80%,
specificity of 97%, and PPV of 72%. This is simi-
lar to previously published reports (Table
1). 9’13-18 Stamm
l summarized 15 Syva DFA
studies in high- and intermediate-prevalence popu-
lations. In high-prevalence populations with a
chlamydia prevalence of 15-26%, the cumulative
sensitivity was 90% and specificity was 95%. The
PPV was 90%. In populations with a prevalence of
9-1 1%, the sensitivity and PPV decreased to 77%
and 79%, respectively.
TABLE I. DFA (Microtrak) studies compared to TC
on endocervical swabs in low-prevalence populations
(< 9%)
No. of
Author patients Prevalence Sensitivity PPV
Gannet al. 268 7 53 69
Lefebvre et al. 715 5 76 76
Phillips et al.
4 527 4 70 62
Forbes et al.s 642 7 60 74
Godfrey et al.
6 332 7 75 95
Graber et al.7 187 8 100 65
Uyeda et al.e 401 7 96 93
aUsed less than ten elemental bodies for a positive test.
The effect of a 3, 12, 24% prevalence on predictive values of an assay
with an 80% sensitivity and a 97% specificity.
A. 3% prevalence (n 1000)
24 29 PPV 45%
6 941 m’v 99%









Fig. 2. How prevalence affects positive predictive value.
Predictive values are influenced by prevalence
rates in a population. 2’6’11 Grimes
19 stated that
when screening for disease in a low-prevalence
population, even with a high sensitivity and speci-
ficity, the PPV would be low. Figure 2 illustrates
how prevalence affects PPV.
When interpreting these data, one must be aware
that TC is not the perfect gold standard. The sensi-
tivity of isolating chlamydia from a single swab is
estimated to be 70--80%.
2,5,6,9 The use of immun-
ofluorescent staining ofTC increases the sensitivity
similar to that of a blind second passage,
l0 Even
with a blind second passage of fluorescent antibody
staining, TC will not identify all infected patients.
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There were 19 false positives; six of these also tested
positive by another antigen detection assay
(TestPack Chlamydia Abbott Labs, Chicago, IL).
Several authors
8’11,12,20--22 have used a second an-
tigen detection assay to demonstrate TC false nega-
tives. If both antigen detection methods were posi-
tive, they would consider the specimen as a true
positive and the TC as a false negative. If these six
specimens are considered true positives, the sensi-
tivity of the Syva DFA increases from 80% to 82%
and the specificity from 97% to 98%. The PPV
increases from 72% to 80%. The original and ad-
justed statistics are not significantly different
(P > 0.0S).
If TC has a sensitivity of 80% and the Syva
DFA assay detects 80% ofTC positives, then only
65% of infected patients are identified with the
DFA assay. This appears to be an unsatisfactory
detection record for a treatable infection that affects
a broad spectrum of society.
Also of concern is the low PPV. Between 20%
and 30% of the Syva DFA positives will be false
positives in this population. A false positive result
on an STD test may have grave social implications.
Thus, some authors advocate TC confirmation of
positive DFA results when used in a low-preva-
lence population.
23 Antigen detection assays have
demonstrated unequivocal false positive results in
patients evaluated for sexual abuse, z4 The Centers
for Disease Control (CDC) recommends only stan-
dard tissue culture methods to identify C. tracho-
marls in the evaluation of sexual abuse, Tissue
culture isolation is still the most sensitive and spe-
cific diagnostic test for chlamydia. 9’1’22
Recent data show that DFA sensitivity may be
increased by the use of the cytobrush to sample the
endocervix. 25’26 The cytobrush was not used in this
study because the manufacturer did not recommend
its use at the initiation of the study. The Syva
Company still does not recommend the use of the
cytobrush in pregnancy.
The results of our study indicate that the Syva
DFA assay lacks the sensitivity and PPV for rou-
tine screening in Ob/Gyn populations with a low
prevalence of C. trachomatis. With the advent of
newer technologies for the detection of chlamydia
(i.e., DNA probes and polymerase chain reaction),
the private practitioner or clinic should critically
analyze the performance of these assays in their
targeted patient population before beginning wide-
spread screening.
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